CTFP Volume 12 Issue 10

CLINICAL THYROIDOLOGY FOR THE PUBLIC
A publication of the American Thyroid Association

Table of Contents

EDITOR’S COMMENTS

Welcome to another issue of Clinical Thyroidology for the Public. In this journal, we will bring to you the most up-to-date, cutting edge thyroid research. We also provide even faster updates of late-breaking thyroid news through Twitter at @thyroidfriends and on Facebook. Our goal is to provide patients with the tools to be the most informed thyroid patient in the waiting room. Also check out our friends in the Alliance for Thyroid Patient Education. The Alliance member groups consist of: the American Thyroid Association, Bite Me Cancer, the Graves’ Disease and Thyroid Foundation, the Light of Life Foundation, MCT8 – AHDS Foundation, ThyCa: Thyroid Cancer Survivors’ Association, Thyroid Cancer Canada, Thyroid Cancer Alliance and Thyroid Federation International.

The American Thyroid Association (ATA) extends its appreciation to all of the patients and their families that are part of the ATA community — our Friends of the ATA. It is for you that the ATA is dedicated to carrying out our mission of providing reliable thyroid information and resources, clinical practice guidelines for thyroid detection and treatments, resources for connecting you with other patients affected by thyroid conditions, and cutting edge thyroid research as we search for better diagnoses and treatment outcomes for thyroid disease and thyroid cancer.

October is Thyroid Nodules Awareness Month.

In this issue, the studies ask the following questions:

  • Do thyroid cancer survivors have a worse quality of life than other cancer survivors?
  • Do low and intermediate risk thyroid cancer patients still need regular neck ultrasounds?
  • How fast do small thyroid cancers grow during active surveillance?
  • Is there any difference in prognosis between focal tall-cell changes and tall-cell variants of papillary cancer?
  • Is the prognosis for multifocal papillary cancer different than for unifocal cancers?
  • Are TPO antibodies associated with worse pregnancy outcomes?

We welcome your feedback and suggestions. Let us know what you want to see in this publication. I hope you find these summaries interesting and informative.

Alan P. Farwell, MD, FACE